Companies / United States

PAH Drug Receives First Approval

June 2007 | Industry News

The US FDA has approved Letairis (ambrisentan0, a new drug from US-based drugmaker

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Industry / United States BMI View: Bristol-Myers Squibb (BMS) is particularly exposed to the patent cliff relative to other multinational pharmaceutical companies. It has little emerging market exposure and is overly reliant on...

February 2011

Positive Results For Eli Lilly Despite The Severity Of Approaching Challenges

Industry / United States BMI View: Eli Lilly's increasing efforts to meet investors' expectations have been reflected in the firm's positive financial results for Q410 and 2010. Net income growth was driven primarily by higher...

February 2011

Amgen Fails To Impress In 2010

Industry / United States BMI View: While Amgen has met its 2010 guidance, weaker than expected Q410 results have dampened investor hopes of a return to stronger growth. Moreover, markedly pessimistic 2011 guidance will further...

January 2011

Johnson & Johnson Ends A Bad Year On A Low

Industry / United States BMI View: Johnson & Johnson (J&J's) Q410 and 2010 financial results have been largely impacted by woeful US sales for the company's consumer healthcare division. However, this does not excuse the...

January 2011

Promising Antidepressant Gains Approval

Industry / United States BMI View: A high proportion of drug candidates fail to display statistically significant efficacy and safety data in late-stage clinical development - the most resource-demanding phase of the drug discovery...

January 2011